SIRPA and rheumatoid arthritis: It was postulated that evaluating the percentage of SIRP/-expressing memory B cells in patients prior to adalimumab treatment could be a valuable biomarker for identifying a subset of active RA patients who will develop ADAs and develop nonresponse to adalimumab (156).